QTc prolongation is a complex problem linked with multiple risk factors. The RISQ-PATH score was previously developed to identify high-risk patients for QTc prolongation. The aim of this study was to optimize and validate this risk score in a large patient cohort, and to propose an algorithm to generate smart QT signals in the electronic medical record.
Introduction
QTc prolongation on the electrocardiogram (ECG) is associated with serious adverse events, especially Torsade de Pointes (TdP) and sudden cardiac death (SCD), but also with an increase in hospital stay and overall mortality [1] . Prolongation of the QTc interval is a complex problem that can be caused by several risk factors, including higher age, cardiovascular and other comorbidities, inherited ion channel disorders and electrolyte disturbances [1] [2] [3] . Furthermore, many drugs are linked with QTc prolongation, as listed in the QT drug lists of Crediblemeds (list 1: drugs with a known risk of QTc prolongation and TdP; list 2: drugs with a known risk of QTc prolongation, not yet linked with TdP (possible risk); list 3: drugs with a conditional risk of TdP) [4] . This risk of QTc prolongation and TdP depends on the underlying repolarization reserve. This concept was introduced by Roden and describes the interplay of different risk factors on the ventricular repolarization, including genetic predisposition. The more risk factors are combined, the lower the repolarization reserve and the higher the risk of QTc prolongation and TdP [2] .
It is a challenge to estimate the individual risk of a certain patient for QTc prolongation. Guidelines recommend ECG monitoring in all patients who receive a drug with a known risk of TdP, especially high-risk patients [1] . However, these high-risk patients are not clearly defined. Several observational studies in clinical practice revealed a low adherence to the guidelines and a limited risk management of QTc prolongation in different settings [5, 6] . The feasibility of the guidelines has therefore been questioned [6] .
Smart clinical decision support systems (CDSS) that take into account the specific characteristics of patients are proposed to help healthcare professionals make safer decisions regarding the risk of QTc prolongation [7] . These tools can help to select high-risk patients and to improve the feasibility of ECG monitoring.
A risk score for QTc prolongation is essential in the design of such an advanced CDSS. A prospective study in the University Hospitals of Leuven led to the development of a preliminary RISQ-PATH score for QTc prolongation, which aims to select high-and low-risk patients for QTc prolongation (a priori prediction of the risk of QTc prolongation) when receiving a prescription for a drug associated with a risk of QTc prolongation and/or TdP [8] . The aim of the current study was to optimize the RISQ-PATH score, by improving the weights allocated to each risk factor, and subsequently to validate this score in a large database of patients who obtained an ECG in a general hospital. The main focus was to acquire a high sensitivity (>85%) while maximizing the specificity of the risk score. The second aim was to integrate this score in an algorithm to form the cornerstone of smart QT signals (which exclude patients with a low risk for QTc prolongation), more specifically an algorithm that would be triggered in the electronic medical record by the prescription of a drug associated with a known risk of QTc prolongation and TdP. Therefore special attention in our analysis went to patients with one or more QTc-prolonging drugs of list 1 of CredibleMeds in their medication profile.
Methods
A retrospective cross-sectional study was performed on data obtained from all Flemish hospitals of the Nexus network. The Nexus network is a group of 17 hospitals in which the same software for electronic medical records (EMR) is used. This EMR software (Klinisch Werkstation, KWS) was developed by the University Hospitals of Leuven.
Data collection
Data were collected from the EMR using predefined criteria. We collected information from all ECGs performed in 2015 in the Nexus hospitals in both ambulatory and hospitalized patients. Along with the information from this ECG (referred to henceforth as 'reference' ECG), data on other risk factors for QTc prolongation were extracted (same risk factors as included in the preliminary RISQ-PATH score [8] ), more specifically previous ECG, age, gender, body mass index
C-reactive protein (CRP, mg l À1 , surrogate indicator for infection/sepsis), estimated glomerular filtration rate (eGFR, ml min À1 ; based on CKD-EPI), cardiovascular history, liver failure, diabetes, neurological disorders, thyroid disturbances and medication associated with a risk of QTc prolongation and/or TdP (lists 1, 2 and 3 of CredibleMeds) [4] . The predefined criteria per risk factor are presented in Table 1 . As the care pathways used to define these criteria have the limitation that a patient can only be included in one care pathway per discipline (e.g. cardiology), (ischaemic) cardiomyopathy and hypertension were pooled together as one risk factor. It was not possible to identify smoking habits reliably within the EMR.
We used the automatic QT (for each lead a median complex based on all normal beats is derived and the QT interval is defined on an overlay of all leads as the time between the earliest detection of depolarization in any lead to the latest detection of repolarization in any lead [defined with the threshold method]) and heart rate measurement (mean heart rate of a 10 s recording) of standard 12-lead resting ECGs (25 mm s À1 paper speed, 10 mm mV À1 amplitude, 250 Hz sampling rate) collected in the clinical routine setting. Different ECG devices were used across the different hospitals. The QT intervals of these ECGs were corrected with the Fridericia (for QRS < 120 ms) or Rautaharju formulae (for QRS ≥ 120 ms) [9] . A moderately prolonged QTc interval was defined as QTc ≥ 450-500 ms (men) or QTc ≥ 470-500 ms (women); a severely prolonged QTc interval as QTc ≥ 500 ms [10] . ECGs with a QTc < 240 ms or > 760 ms were excluded from the database, because these low and high values were considered to be caused by measurement imprecision [11, 12] . Further, patients with an invalid identification number were removed. Each patient was only included once with the last available ECG in 2015. Finally, patients under the age of 18 were excluded from the database.
Statistical methods
Information from a previous ECG, BMI and lab results were missing for a subset of patients. These missing data were completed as a 0 value. In the logistic regression model, extra dummies (factor available = 1, not available = 0) were added to take the absence of these data into account (the missing indicator method).
The preliminary RISQ-PATH score was computed (see Appendix S1) and patients with a score <10 points were defined as having a low risk for QTc prolongation [8] . The performance characteristics of this risk score (area under the ROC-curve [AUC, before dichotomization], sensitivity, specificity, positive and negative predictive value [PPV and NPV]) to predict a prolonged QTc interval (both defined as ≥450(♂)/470(♀)ms and ≥500 ms) in the reference ECG were analysed. These analyses were performed for all patients and for a subset of patients without missing data.
To optimize the RISQ-PATH score, a multiple logistic regression model to predict a QTc ≥ 450(♂)/470(♀) ms in the reference ECG, based on the individual risk factors, was used. We first considered developing a model to predict for QTc ≥ 500 ms but, given the low number of cases compared to the number of considered predictors (<50 cases per degree of freedom), this model was not deemed reliable.
In the first step, the following factors were incorporated in the model: availability of a previous ECG (0 or 1); QTc on a previous ECG ≥ 450(♂)/470(♀) ms and < 500 ms (0 or 1); QTc on a previous ECG ≥500 ms ( 
Number of drugs of list 1, 2 or 3 of CredibleMeds
Current medication data BMI, body mass index; CRP, C-reactive protein; ECG, electrocardiography; EF, ejection fraction; eGFR, estimated glomerular filtration rate based on CKD-EPI [13] . Factors described with several dummies were only excluded if all dummies had a p-value of >0.157. All pairwise correlations (Phi coefficient) between predictors were verified, ranging from À0.1575 to 0.3105. Finally, no significant interactions between the risk factors were identified, so no interactions were added to the model. Based on the predicted probabilities of the model and with the help of an ROC curve, a suitable cutoff value (focus on sensitivity) for a high risk of QTc prolongation was identified. The performance characteristics of the RISQ-PATH model (AUC before dichotomization, sensitivity, specificity, PPV and NPV) to predict a prolonged QTc interval (≥450(♂)/470(♀) ms and ≥ 500 ms) in the reference ECG were calculated.
The performance characteristics of the RISQ-PATH model were studied in three subgroups: patients with a previous ECG available and patients taking ≥1 and ≥2 drug(s) of list 1 of Crediblemeds. These last two groups were selected because one of the ideas is that a future CDSS should be triggered by the prescription of a drug with a known risk of QTc prolongation and TdP.
To validate our findings, a second validation dataset was obtained for the period January-April 2016. The same inclusion and exclusion criteria were used as in the training database and missing data were handled in the same way.
Finally, the RISQ-PATH model was applied on the data of the prospective RISQ-PATH study, in which hospitalized patients (n = 178) who received an acute drug associated with a risk of QTc prolongation and/or TdP (list 1, 2 and 3 of Crediblemeds) were studied with a baseline and follow-up ECG [8] .
Data analysis was performed using Microsoft Excel and SPSS23 for Windows. Data are presented as mean ± standard deviation (SD), median + range, odds ratio (OR) + 95% confidence intervals (95% CI) or sensitivity/specificity/PPV/NPV + 95% CI.
Ethical committee
The study protocol of this retrospective study was approved by the ethics committee of the University Hospitals Leuven (s56032, ML9989, 01/03/2016).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [14] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2017/18 [15, 16] .
Results

Patient characteristics
In total, 60 208 patients (52.8% males, mean age 63 ± 18 years, range 18-115 years) were included in the dataset. The flow diagram of inclusions is presented in Figure 1A (exclusion of ECGs with a QTc < 240 ms or > 760 ms: n = 590). The risk factors of these patients, including the number of missing data, are presented in Table 2 . A subset of 5418 patients (55.7% males, mean age 68 ± 16 years, range 18-103 years) had no missing values.
The mean QTc interval in the reference ECG was 414.6 ± 27.8 ms; 3543 patients (5.9%) had a QTc ≥ 450(♂)/ 470(♀) ms and 453 (0.8%) a QTc ≥ 500 ms on this ECG. Histograms of the QTc intervals in the reference ECG and delta QTc with the previous ECG are presented in Figure 2 .
Performance of the preliminary RISQ-PATH score
The performance characteristics of the preliminary RISQ-PATH score, both for all patients and the subset of patients without missing data, can be found in Appendix S2. Of all patients, 50 961 (84.6%) had a preliminary RISQ-PATH score < 10 points. This cutoff led to a sensitivity of 40 
Multiple logistic regression and development of the RISQ-PATH model
The results of the multiple logistic regression are displayed in Table 3 (Panel A presents the results when all risk factors are included in the model; Panel B presents the results after step-by-step exclusion of non-significant factors). The predicted probability (π) to have a QTc ≥ 450(♂)/470(♀) ms in the reference ECG (X) can be obtained using the following formula: BMI, body mass index; CRP, C-reactive protein; ECG, electrocardiography; eGFR, estimated glomerular filtration rate based on CKD-EPI
Figure 2
Histograms of the QTc intervals in the reference ECG (A, n = 60 208) and the delta QTc with the previous ECG (B, n = 18 429) The RISQ-PATH-model for QTc prolongation The RISQ-PATH model has an AUC of 0.772 [95% CI 0.763-0.780]. Based on this ROC curve, a predicted probability of 0.035 or higher was set as cutoff for a high risk of QTc prolongation. In total, 33 567 patients (55.8%) had a predicted probability of ≥0.035, including all patients with a prolonged QTc in a previous ECG. The performance characteristics of the RISQ-PATH model are presented in Table 4 . The RISQ-PATH-model for QTc prolongation one or more QTc-prolonging drugs of list 1 in their medication profile. Figure 1B gives an overview of the inclusions in the validation database. In total, 28 400 patients (53.1% males, mean age 64 ± 17 years, range 18-126 years) were included. The characteristics of these patients are presented in In the previously performed prospective RISQ-PATH study, the current RISQ-PATH model was able to predict, based on baseline data, all cases in which a prolonged QTc ≥ 450(♂)/470(♀) ms developed after the start of a drug associated with a risk of QTc prolongation and/or TdP (n = 26) with a sensitivity of 100. 
Validation of the RISQ-PATH model
Discussion
In the large training subset, 5.9% of patients had a QTc ≥ 450(♂)/470(♀) ms on their reference ECG; in 0.8% of patients the QTc was ≥ 500 ms. Risk factors for QTc prolongation were common among the patients in the training subset; more than 17% of patients were treated with one or more drugs in list 1 of Crediblemeds.
A logistic regression model (the optimized RISQ-PATH model) with an AUC of 0.772 was used for further analysis. With this model and a cutoff probability of 0.035 for high risk, a prolonged QTc in the reference ECG could be predicted with a sensitivity of 87.4% and a specificity of 46.2%. These findings were confirmed in a large validation database and on data from a smaller but prospective study.
The preliminary RISQ-PATH score
To design an advanced CDSS for QTc prolongation, a risk score that enables the distinction between high-and low-risk patients for developing QTc prolongation is essential. Both Tisdale et al. and Haugaa et al. already introduced a risk score for QTc prolongation [17, 18] . The risk score of Tisdale et al. was specifically developed for cardiac intensive care patients [17] . The pro-QTc score of Haugaa et al. was developed in a general hospital population and increased mortality was associated with high values for the pro-QTc score. However, no results on the prediction performance (sensibility and specificity) of the pro-QTc score were found and the weighting of the different risk factors was limited [18] . Therefore, we previously developed a preliminary RISQ-PATH score in a prospective observational study in the University Hospitals of Leuven (RISQ-PATH study), which aims to select high-and low-risk patients for QTc prolongation (a priori prediction of the risk of QTc prolongation) when receiving a prescription for a drug associated with a risk of QTc prolongation and/or TdP [8] .
In the current study, the preliminary RISQ-PATH score resulted in an AUC of 0.702 which is slightly lower than the AUC in the RISQ-PATH study. Taking into account all patients and using a cutoff of 10 points, a sensitivity of 40.3% and a specificity of 86.2% was found. However, if only the patients with complete data were included, the sensitivity and specificity of the preliminary RISQ-PATH score respectively improved to 78.4% and 52.3%. These last results are more in line with the sensitivity and specificity obtained in the original RISQ-PATH study. Consequently, a cutoff of 10 points is probably only a good choice in patients without missing data.
Based on these results, we decided to develop an optimized RISQ-PATH model to achieve a better prediction of QTc prolongation, also applicable for patients with missing data.
An optimized and validated RISQ-PATH model
Multiple logistic regression was used to develop the most optimal prediction model. Important predictors in the model are a prolonged QTc interval on a previous ECG, age ≥ 65 years, hypokalaemia, history of arrhythmias and liver failure. Diabetes, thyroid disturbances and drugs on list 2 of CredibleMeds were excluded from the model.
The multiple logistic regression model showed that the availability of a previous ECG or an eGFR measurement decreases the risk of QTc prolongation. This could possibly be explained by the fact that, when the results of a previous ECG or the eGFR are known, physicians are more careful with the prescription of new drugs which could lead to QTc prolongation. In contrast, the availability of a potassium and CRP measurement seems to lead to a higher risk. These measurements are probably performed more often in sicker patients, explaining the higher risk of QTc prolongation. Further, the model allocates only a small weight to the number of drugs associated with a risk of QTc prolongation and/or TdP. From our data, it seems that the cumulative effect of taking more than one of these drugs remains limited. This is in line with our previous results [8] . Due to the different mechanisms for the inhibition of hERG-channels (pore blockers, gate modifiers, etc.) and other channels [2, 3, 19] , it is difficult to determine the precise effect size of each individual drug and the combination of several drugs associated with a risk of QTc prolongation and/or TdP. At the moment, the QT drug lists of CredibleMeds [4] seem to be the best method to categorize QTc-prolonging drugs and to make a distinction in weight between these drugs. In our model, only list 1 and list 3 drugs were identified as significant predictors. This might be due to the low use of list 2 drugs in the Nexus hospitals (3.8% of the patients) in comparison with list 1 and list 3 drugs (respectively 17.2% and 15.4% of the patients).
The RISQ-PATH model resulted in a prediction with an AUC of 0.772. The cutoff probability of the model was set at 0.035 as high risk for QTc prolongation on the reference ECG. This cutoff resulted in a sensitivity of 87.4% and a specificity of 46.2% for the prediction of a QTc ≥ 450/470 ms. Moreover, the performance characteristics also remained acceptable for the prediction of a QTc ≥ 500 ms (sensitivity: 88.5%; specificity: 44.5%, NPV: 99.8%).
Similar results were found in the validation database with a sensitivity of 88.4% and a specificity of 43.8%. In addition, using the data from the initial prospective RISQ-PATH study, all cases of QTc prolongation (n = 26) after the start of an acute QTc-prolonging drug were predicted with the RISQ-PATH model.
Based on current knowledge and the available risk factors in the EMR, the RISQ-PATH model is the best optimized prediction of QTc prolongation that we can offer in the studied clinical setting.
Future perspectives: translation of the RISQ-PATH model in a CDSS
From the perspective of patient safety, we aimed for a model with a high sensitivity and a low number of false negatives. The proposed cutoff point resulted in a sensitivity of 85-90%; consequently, the specificity is limited to 40-50%. Applying a prescription for a drug of list 1 as a trigger, this specificity is further reduced to 30%. However, this still means that, in comparison with a standard alert system that does not take into account the individual risk factors and that would generate a warning upon any prescription of a list 1 drug, the number of alerts should at least be reduced by 30%. We are planning to test other methodologies (e.g. machine-learning techniques) to further improve the prediction characteristics of the RISQ-PATH model.
Based on the current RISQ-PATH model, we already developed a proposal for an algorithm for a CDSS, as presented in Figure 3 . The idea is that the algorithm would run when a prescription of a list 1 drug is generated. Depending on the predicted probability in the RISQ-PATH model, an alert would be generated for the prescribing physician. Consequently, for patients with a low risk for QTc prolongation, no alert will appear. The predicted probability would be calculated in the background of the EMR with the most recent information on each predictive factor (e.g. latest ECG, latest lab result, most recent list of medications). In that way, the most upto-date predicted probability would always be available. The alert itself should clearly display the risk factors of the patient that constitute the risk and the number and type of missing data. Further, possible actions should be suggested. As the model also takes into account the combination of multiple QTc-prolonging drugs, these alerts could be an optimization of the current drug-drug interaction alerts for the risk of QTc prolongation.
Figure 3
Proposal of an algorithm for a CDSS, based on the RISQ-PATH model
The RISQ-PATH-model for QTc prolongation Off course, the prescription of a list 1 drug should not be the only trigger for a thorough follow-up of patients with a risk of QTc prolongation. Another CDSS could also give alerts for each ECG with a QTc interval <300 ms or ≥500 ms. These ECGs should always be checked by the responsible clinician. In the Mayo Clinics, similar alert systems were succesfully implemented, resulting in a significant decrease in the use of QTc-prolonging drugs in patients with a history of a QTc ≥ 500 ms [18, 20] . In addition, electrolyte disturbances (e.g. hypokalemia) could also be a useful trigger for a CDSS.
Finally, clinicians might find the RISQ-PATH model more difficult to work with in clinical practice than the RISQ-PATH score which allocated integers per factor. However, if the RISQ-PATH model is incorporated in a computerized algorithm or online calculator, the predicted probability can easily be calculated. Moreover, each institution that wants to implement a CDSS based on the RISQ-PATH model can decide on its own balance in sensitivity and specificity and choose its own optimal cutoff point in the predicted probability.
Strengths and limitations of the study
The major strengths of this retrospective study are the large number of included patients and the high number of cases of QTc prolongation. Moreover, these data were collected in 17 general hospitals in Belgium. The broad study population (patients from different hospitals and wards) on which the model was built, can be considered as both a strength and a weakness of the study. Although the RISQ-PATH model will be applicable in a general hospital population (taking into account missing data), it may overlook factors that are only relevant in certain sub-populations resulting in a lower specificity of the model in that setting. All risk factors were defined with clear criteria to make it possible to automatically extract these factors from the EMR. The EMR allows use of these parameters in CDSS, with the possibility to create smart alerts in the electronic prescribing system. Although the considerable amount of missing data can be considered as a limitation of the study, a strategy (the missing-indicator method) was applied to deal with these missing values (which is also a strength as it broadens the applicability of the model). This method was chosen instead of imputation of missing values and despite the potential bias reported in the literature [21] , because the absence of risk factors can also be informative for the risk of QTc prolongation. Finally, a second retrospective dataset and a prospective dataset were used to validate the optimized RISQ-PATH model. Some limitations should be acknowledged. It has been suggested that integration of pharmacokinetic aspects of drugs/treatment (exposure, administration, pharmacokinetic drug-drug interactions) and information on genetic predisposition (silent mutations in LQTS-genes, CYP-polymorphism) might further improve the prediction of QTc prolongation and TdP [3, 22] . However, at the moment, it is not clear how these factors should be incorporated in a prediction model. Moreover, genetic information is not available for most patients. Undoubtedly, this will be the subject of future studies and might improve the prediction model in the future. Additionally, smoking habits could not be extracted reliably, as these were not registered in a structured way in the EMR of the hospitals that took part in the study. As explained in the methods section, the risk factors cardiomyopathy and hypertension were pooled. Further, we relied on automatic measurements of QT and heart rate (with different ECG devices in the different hospitals), as manual correction could not be performed in this large database. To improve the accuracy of the included ECGs, ECGs with a QTc interval <240 ms and >760 ms were excluded. However, measurement imprecision of the QT interval could also have occurred in the other ECGs, especially with bifid or flat T-waves [23] .
Finally, it must be acknowledged that QTc prolongation is an imperfect marker of TdP. For most drugs, there is no linear relationship between the QTc value and the risk of TdP, and not all QTc-prolonging drugs are linked with TdP. Nevertheless, guidelines agree that the risk of QTc prolongation should be taken into account in the prevention of ventricular arrhythmias and sudden cardiac death [1, 24, 25] . In the current study, it was not possible to validate the RISQ-PATH model using clinical events as hard end-points. This should be the subject of future studies.
Conclusion
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